Background. Atrial fibrillation (AF) is associated with endothelial dysfunctions.
Introduction
Endothelium, the innermost layer of the vessels, is responsible for the proper functioning of the cardiovascular system. Its paracrine and endocrine signaling regulates the blood flow, local inflammation response and hemostasis. Endothelial function assessment may be a part of risk stratification in patients with cardiovascular diseases. 1 Numerous techniques are used for endothelial function evaluation. One of them is the assessment of serum level of endothelium-related biomarkers. Endothelin type 1 (ET-1), protein synthetized and secreted by endothelial cells is a specific and sensitive marker of endothelial dysfunction. 2 It promotes vasoconstrictions, activates platelets and also influences on myocardial fibrosis. 3 Endothelial function is also strictly connected with thrombomodulin (TM) serum level, which is elevated during endothelial cells damage. This surface protein has significant anticoagulant properties, which balance procoagulant activities of endothelial dysfunction. 4 Vascular endothelial grow factor (VEGF) plays a potent role in angiogenesis, endothelial cells proliferation and nitric oxide synthesis by endothelial cells. 5 Decreased VEGF serum level is the marker of abnormal endothelial function.
Atrial fibrillation (AF) is the most common supraventricular arrhythmia, which occurs in 1.5-2% of population. 6 Moreover, AF is one of the cardiovascular diseases in which endothelial dysfunction is well proven. 7 Previous studies have shown that abnormal endothelial function predisposes the patient to atrial tissue fibrosis, which is a dominant factor responsible for the conversion of paroxysmal to persistent form of the arrhythmia. 8 However, there is no data on endothelial function changes connected with AF.
The aim of the presented study was to check the potential influence of AF duration on endothelial function, assessed with the serum biomarkers' levels. Influence of total AF duration on endothelial function was additionally assessed.
Material and methods

Study population
Endothelial function was prospectively evaluated in a group of 65 consecutive patients with persistent AF, qualified for the percutaneous pulmonary veins isolation between April 2013 and December 2014. According to current guidelines of the European Society of Cardiology, persistent AF was defined as AF episode lasting longer than 7 days or terminated by cardioversion. 9 Inclusion of the patients was limited to the cases with AF episode lasting longer than 7 days. Qualification for invasive treatment of AF was based on the guidelines of the European Society of Cardiology. 9 Exclusion criteria included: neoplastic disease and persistent inflammatory state.
The study was approved by Ethical Review Board (35/2013).
Clinical assessment during hospitalization
All data according to clinical state, medical history and concomitant diseases was obtained during the hospitalization during which percutaneous pulmonary veins isolation was performed. The baseline laboratory tests included: blood cell morphology, ion levels, liver enzymes activities, creatinine concentration and coagulation tests. The baseline characteristics of patients are presented in Table 1 .
Duration of atrial fibrillation episode and total atrial fibrillation duration
Data concerning the duration of atrial fibrillation episode and total atrial fibrillation was based on patients' interviews and medical documentation. To analyze the trends for the concentrations of endothelial function biomarkers, patients were divided into three groups consistent with the duration of AF episode tertiles and the total duration of AF tertiles. In the case of a lack of data about the duration of last AF episode or total AF, patients were excluded from the particular analysis.
Measurements of the biomarkers' levels
Venous blood samples (5 mL) were collected at the beginning of the ablation procedure from the vascular sheet placed in the femoral vein. After clotting, all samples were centrifuged for 15 min at 1000 × g. Serum was removed from the sample directly after centrifugation and stored at the temper- 
Statistical analysis
Continuous variables were presented as mean value ± standard deviation or as a median and interquartile range (IQR), when normally or non-normally distributed, respectively. Normal distribution of variables was assessed using the Shapiro-Wilk test. Categorical data was presented as absolute and relative frequencies. Statistical significance of trends across increasing duration of AF episode and total AF was assessed: for quantitative variables with Jonckheere-Terpstra test and for qualitative variables -with Cochran-Armitage test for trend. A value of p < 0.05 was considered significant for all tests. Statistical analysis was performed using SAS ® software, v. 9.4.
Results
A total of 65 patients were included in the analysis. The median age was 56 (49-61) years with 84.6% of males. Median durations of last AF episode and total AF were 10 (6-19) ranged from 1 to 72 years and 49 (31-72) ranged from 3 to 240 years, respectively. Median values of ET-1, TM and VEGF were 3.1 (2.5-3.5) pg/mL, 3126.0 (2827.2-3594.1) pg/mL and 464.6 (323.6-630.1), respectively.
Comparison of the groups based on the duration of atrial fibrillation episode
The analyzed group was divided into 3 subgroups by increasing time of the duration od AF episode. To obtain closest to equal number of patients in each subgroup we used time ranges as follows: ≤ 7 months (n = 24 patients), from 7 to 14 months (n = 18 patients) and ≥ 14 months (n = 23 patients). In patients with longer lasting AF episodes we observed a higher body mass index (BMI), less incidence of heart failure and trends towards less frequent usage of calcium channels blockers, angiotensin II receptor blockers, aldosterone antagonists and diuretics. Full comparison of the formed subgroups is presented in 
Endothelial function in groups based on total atrial fibrillation duration
Information about total AF duration was obtained in 59 patients. To assess the influence of total AF duration on endothelial function biomarkers concentrations, we divided the analyzed group into three equal subgroups based on AF duration criteria: ≤ 44 months (n = 21 patients), from 44 to 72 months (n = 18 patients) and ≥ 72 months (n = 22 patients). Comparison of subgroup revealed no statistically significant differences between the subgroup according to clinical characteristics, laboratory test results and pharmacotherapy. There was only a trend towards lower usage of calcium channel blockers in patients with longer lasting AF. We observed no significant differences in ET-1, TM and VEGF serum concentrations between groups. However, patients with longer lasting AF presented lower levels of ET-1 and TM (Table 3) .
Discussion
To the best of our knowledge, this is the first study describing the effects of AF episode duration on endothelial function. The main finding of this study is that the duration of AF episode may influence the endothelial function, assessed by serum concentration of biomarkers. Moreover, we indicated no association between total atrial fibrillation duration and endothelial function.
ET-1, because of its pro-fibrotic properties, may lead to atrial remodeling. Previous studies demonstrated also the influence of endothelial dysfunction on electrical remodeling. 9 Both of these factors contribute to AF chronicity. 10 However, there is still not enough data focusing on endothelial dysfunction in chronic form of AF. The effect of long lasting AF episode on ET-1 serum concentrations presented in the study seems to be unexpected. Because relatively short plasma half-life of ET-1 (about 1.5 min), the elevated serum level of this biomarker in the cardiovascular diseases seems to be associated with increased gene expression. 11, 12 Mayyas et al. analyzed the left atrial appendage (LAA) tissue collected during cardiac surgery procedures to show a higher ET-1 concentration in the group of patients with permanent AF then with paroxysmal AF. 13 However, there was no sig- Table 3 . Comparison of groups consistent with duration of total atrial fibrillation tertiles nificant difference between ET-1 tissue concentrations in persistent and paroxysmal AF patients. Partially, higher ET-1 level may be related to the prevalence of concomitant diseases in the group of patients with permanent AF. Previous studies showed no relation between successful cardioversion of persistent AF and short-term reduction of ET-1 concentration. 14 However, Dezsi et al. presented a rapid decrease of ET-1 level after catheter ablation or modification of atrio-ventricular junction due to supraventricular arrhythmias. 15 The authors suggest that the heart rhythm is strictly associated with serum ET-1 level. Therefore, a longer lasting episode of AF may result in the adaptation to potential tachyarrhythmia and also in the reduction of ET-1 synthesis.
Mondilo et al. presented that the serum level of TM is significantly higher in patients with chronic, nonrheumatic AF compared with control subjects with sinus rhythm. 16 By its anticoagulant properties, TM plays an important role in the prevention of thromboembolic events, which are essential a complication of AF. 6 The lower serum level of TM is associated with endothelial dysfunction and also with an increased procoagulant state. In the presented study we did not reveal a significant correlation between the duration of the AF episode and TM serum level. According to our results, it seems that coagulant properties measured by TM concentration may not be associated with the duration of chronic arrhythmia.
VEGF has vast effects in patients with AF. It promotes an inflammatory response, endothelium proliferation, angiogenesis and also plays a dual role in the coagulant pathway.
17, 18 Scridon A, et al. assessed the VEGF level in particular parts of the vascular system in patients with AF. 19 Serum concentration of VEGF in the left atrium was significantly higher in patients with paroxysmal AF, compared with control subjects. Interestingly, the VEGF levels in patients with persistent AF and control subjects were similar. Authors colligated higher concentrations of VEGF with pulsatile vascular and atrial stretch. In patients with persistent AF, due to atrial fibrosis, pulsatile stress is decreased. It may results in lower concentrations of VEGF. Results of our study confirmed this theory. We observed a trend toward lower VEGF serum levels in patients with longer lasting AF episode.
The presented study indicated that the duration of AF episode may be associated with endothelial function, assessed by serum biomarkers. ET-1 serum concentrations were significantly lower in patients with longer episodes of AF. We did not find correlations between endothelial function and total AF duration.
Study limitations
One of the main limitations of the presented study was the precise assessment of AF episodes duration. We tried to obtain this data based on medical documentation. However, this was not possible for every patient.
In these situations, the medical history, including performed procedures and symptoms of the arrhythmia, was collected.
Authors were also faced with the inability to create three groups with equal number of patients consistent with the duration of the AF episode. This situation was associated with the inclusion of patients with the same duration of AF episodes. However, methods of subgroup formation were planned to obtain the maximal equality of the number of patients inside the groups.
A certain restriction of our research was the small size of the groups. Probably because of the association of serum VEGF level with AF episode, the duration did not reach statistical significance.
Obviously some of concomitant diseases may influence the endothelial function. To reduce this bias, the authors focused on a group of patients with persistent AF treated with pulmonary veins isolation. Patients who qualified for this procedure are relatively young and the incidence of diseases, which can influence endothelial function, is low.
